Toronto, Ontario--(Newsfile Corp. - November 7, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") announces that a notice of requisition of a meeting of shareholders (the "Requisition") was delivered to the registered office of the Company on November 3, 2025.
The Requisition has been made by Frank Teti and Franmar Properties Ltd. (collectively the "Concerned Shareholders") which requires that the Company call and hold a meeting of shareholders pursuant to section 105(1) of the Business Corporations Act (Ontario) (the "Act"). The purpose of the proposed meeting is to: (i) pass an ordinary resolution to remove all five (5) incumbent directors from the Board; and (ii) to elect Claude Ayache, Rob Saltsman, Jeff Stevens, Sheldon Levy, and Tasheel Jeerh as director nominees replacing the incumbent directors.
The Company is reviewing the Requisition and will respond within the time required by the Act.
About LevelJump Healthcare
LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its Diagnostic Centres. JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve.
ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.
Mitchell Geisler
Chief Executive Officer
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: 647-340-2020
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).
Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
| Last Trade: | C$0.05 |
| Daily Volume: | 0 |
| Market Cap: | C$4.820M |
November 10, 2025 August 29, 2025 June 20, 2025 June 13, 2025 December 02, 2024 | |

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load